Salarius Pharmaceuticals (SLRX)
(Delayed Data from NSDQ)
$1.71 USD
-0.04 (-2.29%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Salarius Pharmaceuticals, Inc. [SLRX]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Additional Early-Stage Clinical Findings and FDA Type B Meeting Provide Clarity Around Trial Advancements
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Additional Early-Stage Clinical Findings and FDA Type B Meeting Provide Clarity Around Trial Advancements
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 2023 Financial Result Update, Program Advancements and Strategic Shifts
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Continued Progress Highlighted by Significant Milestone
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Promising Preclinical Data for SalariusPharmaceuticals'' Novel Molecular Glue, SP-3164, Presented at EHA 2023
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Removes Seclidemstat Partial Clinical Hold and Company Achieves Further Progress Across Clinical Pipeline
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Pre-clinical Trial Results Demonstrating SP-3164?s Compelling Anti-Tumor Activity
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Presentation of In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging SP-3164 Preclinical Trial Data Presentation and Expansion of Intellectual Property Protection
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Interim Results from Phase 1/2 Trial of Seclidemstat
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Showcasing Novel Compound with Potential for Improved Anti-Cancer Activity
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pause in New Patient Enrollment in Seclidemstat Trial.
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Salarius Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Significant Development of Existing Programs with Data Updates Anticipated in 2022
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H